Krabbe Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | AlaMab Therapeutics, Zentalis Pharmaceuticals, Isofol Medical, Merck, Eisai

Krabbe Disease companies are Jiangsu Hengrui Medicine, AstraZeneca, Y-mAbs Therapeutics, Innovent Biologics, PersonGen BioTherapeutics (Suzhou), Cellectar Biosciences, Inc., MacroGenics, Shanghai Pharmaceuticals Holding, Celgene, Hutchmed, MedImmune LLC, Lee's Pharmaceutical Limited, EMD Serono, Iovance Biotherapeutics, Inc., BioEclipse Therapeutics, BioAtla, Inc., Celgene, Actuate Therapeutics Inc., and others.
According to DelveInsight, the Krabbe Disease pipeline includes over eight leading companies actively engaged in developing more than eight treatment therapies for the condition.

Krabbe Disease Overview:

Krabbe disease includes a spectrum of disorders, ranging from infantile-onset-marked by severe symptoms like extreme irritability, muscle stiffness (spasticity), and developmental delays appearing before 12 months of age-to later-onset forms, which can emerge anytime after the first year of life, even into the seventh decade. Traditionally, enzyme activity testing has shown that 85%-90% of symptomatic cases are infantile-onset, with only 10%-15% being later-onset. However, findings from newborn screening (NBS) suggest that later-onset cases may be more common than previously thought. Infantile-onset typically starts with normal development, followed by rapid neurological deterioration, and an average life expectancy of about 24 months (with a range from 8 months to 9 years). Later-onset forms of the disease are more variable in both symptoms and disease progression.

Request for a detailed insights report on Krabbe Disease pipeline insights [https://www.delveinsight.com/report-store/krabbe-disease-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

"Krabbe Disease Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Krabbe Disease Therapeutics Market.

Key Takeaways from the Krabbe Disease Pipeline Report

*
DelveInsight's Krabbe Disease pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Krabbe Disease treatment.

*
In January 2025, The FDA awarded breakthrough therapy designation (BTD) to GSK5764227 (GSK'227) for treating adult patients with relapsed or refractory Krabbe Disease who have experienced disease progression after receiving at least two previous treatment regimens.

*
Key Krabbe Disease companies such as Forge Biologics, Passage Bio, Sanbio, Polaryx, Gain Therapeutics, and others are evaluating new drugs for Krabbe Disease to improve the treatment landscape.

*
Promising Krabbe Disease pipeline therapies in various stages of development include FBX-101, PBKR03, and others.

Krabbe Disease Pipeline Analysis

The report provides insights into:

*
The report provides detailed insights into the key companies that are developing therapies in the Krabbe Disease Market.

*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Krabbe Disease treatment.

*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Krabbe Disease market.

Download our free sample page report on Krabbe Disease pipeline insights [https://www.delveinsight.com/sample-request/krabbe-disease-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Krabbe Disease Emerging Drugs

*
FBX-101: Forge Biologics

*
PBKR03: Passage Bio

Krabbe Disease Companies

Approximately eight major companies are actively working on developing treatments for Krabbe disease. Of these, Passage Bio has the most advanced drug candidates, currently in Phase I/II of clinical development.

DelveInsight's report covers around 22+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Krabbe Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Krabbe Disease Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Krabbe Disease Therapies and Key Companies: Krabbe Disease Clinical Trials and advancements [https://www.delveinsight.com/report-store/krabbe-disease-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Krabbe Disease Pipeline Therapeutic Assessment

- Krabbe Disease Assessment by Product Type

- Krabbe Disease By Stage

- Krabbe Disease Assessment by Route of Administration

- Krabbe Disease Assessment by Molecule Type

Download Krabbe Disease Sample report to know in detail about the Krabbe Disease treatment market @ Krabbe Disease Therapeutic Assessment [https://www.delveinsight.com/sample-request/krabbe-disease-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Krabbe Disease Current Treatment Patterns

4. Krabbe Disease - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Krabbe Disease Late-Stage Products (Phase-III)

7. Krabbe Disease Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Krabbe Disease Discontinued Products

13. Krabbe Disease Product Profiles

14. Krabbe Disease Key Companies

15. Krabbe Disease Key Products

16. Dormant and Discontinued Products

17. Krabbe Disease Unmet Needs

18. Krabbe Disease Future Perspectives

19. Krabbe Disease Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Krabbe Disease Pipeline Reports Offerings [https://www.delveinsight.com/report-store/krabbe-disease-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=krabbe-disease-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-alamab-therapeutics-zentalis-pharmaceuticals-isofol-medical-merck-eisai]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.